- Home
- HUBS vs ARGX Comparison
HUBS vs ARGX Comparison
Compare HUBS & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUBS
- ARGX
- Stock Information
- Founded
- HUBS 2005
- ARGX 2008
- Country
- HUBS United States
- ARGX Netherlands
- Employees
- HUBS N/A
- ARGX N/A
- Industry
- HUBS Computer Software: Prepackaged Software
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HUBS Technology
- ARGX Health Care
- Exchange
- HUBS Nasdaq
- ARGX Nasdaq
- Market Cap
- HUBS 39.2B
- ARGX 37.3B
- IPO Year
- HUBS 2014
- ARGX 2017
- Fundamental
- Price
- HUBS $772.24
- ARGX $665.68
- Analyst Decision
- HUBS Buy
- ARGX Strong Buy
- Analyst Count
- HUBS 23
- ARGX 20
- Target Price
- HUBS $722.57
- ARGX $653.11
- AVG Volume (30 Days)
- HUBS 412.4K
- ARGX 273.4K
- Earning Date
- HUBS 02-12-2025
- ARGX 02-27-2025
- Dividend Yield
- HUBS N/A
- ARGX N/A
- EPS Growth
- HUBS N/A
- ARGX N/A
- EPS
- HUBS N/A
- ARGX N/A
- Revenue
- HUBS $2,506,280,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- HUBS $22.11
- ARGX $73.18
- Revenue Next Year
- HUBS $15.70
- ARGX $55.26
- P/E Ratio
- HUBS N/A
- ARGX N/A
- Revenue Growth
- HUBS 21.78
- ARGX 85.56
- 52 Week Low
- HUBS $434.84
- ARGX $349.86
- 52 Week High
- HUBS $811.79
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- HUBS 63.73
- ARGX 63.36
- Support Level
- HUBS $715.21
- ARGX $641.76
- Resistance Level
- HUBS $811.79
- ARGX $661.59
- Average True Range (ATR)
- HUBS 23.60
- ARGX 16.10
- MACD
- HUBS 7.00
- ARGX -0.70
- Stochastic Oscillator
- HUBS 68.60
- ARGX 70.42
About HUBS HubSpot Inc.
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.